Cardio Diagnostics Holdings Inc (CDIO)vsMerck & Company Inc (MRK)
CDIO
Cardio Diagnostics Holdings Inc
$1.58
+1.28%
HEALTHCARE · Cap: $4.82M
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 397149671% more annual revenue ($65.77B vs $16,560). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
CDIO
Avoid33
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.0%
Fair Value
$2.64
Current Price
$1.58
$1.06 discount
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 185.1% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDIO
The strongest argument for CDIO centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 185.1% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : CDIO
The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CDIO profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
CDIO carries more volatility with a beta of 2.18 — expect wider price swings.
CDIO is growing revenue faster at 185.1% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 33/100). CDIO offers better value entry with a 50.0% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cardio Diagnostics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology company dedicated to improving cardiovascular health through advanced diagnostic solutions. By harnessing cutting-edge technology, CDIO provides healthcare professionals with essential tools for accurate assessment and effective management of cardiovascular diseases, ultimately enhancing patient outcomes. With a strong focus on personalized medicine, the company is strategically poised for substantial growth, representing a compelling investment opportunity for institutional investors aiming to leverage advancements in the evolving healthcare landscape.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?